InnovationRx: Tarsus Pharmaceuticals Takes Aim At Disease-Causing Bugs [Forbes]
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: Forbes
A round 25 million Americans are affected by the eye disease Demodex blepharitis , which is caused by small mites that make their way into the eyelid. This causes chronic inflammation that can, in severe cases, cause problems on the cornea of the eye itself. The disease can also cause damage to eyelashes and cause other allergic reactions. Despite its prevalence, there wasn't any good treatment for the disease until July of last year , when the Tarsus Pharmaceuticals' Xdemvy , an eyedrop solution that directly targets the mites that cause the disease. The treatment hit the market in late August 2023. Since then, CEO Bobak Azamian told Forbes , the company has been busy getting the treatment to patients. “We did $25 million in revenue in the first quarter,” he said. “That was a nearly 90% increase from the fourth quarter.” That figure represents getting the drug to over people with the disease, with over 8,000 eye doctors beginning to provide the drug to patients, he said. He adde
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Tarsus to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Tarsus to Participate in Upcoming Investor ConferencesGlobeNewswire
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at HC Wainwright from $57.00 to $61.00. They now have a "buy" rating on the stock.MarketBeat
- Earnings Update: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported And Analysts Are Boosting Their Estimates [Yahoo! Finance]Yahoo! Finance
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at Barclays PLC from $50.00 to $60.00. They now have an "overweight" rating on the stock.MarketBeat
TARS
Earnings
- 5/8/24 - Beat
TARS
Sec Filings
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- TARS's page on the SEC website